Skip to content
SYS_TIME: 00:00:00.00//LATENCY: 24MS//NODES: 142//BTC_HASH: 000000000000//TZ: UTC//
X: -100Y: -100
All dispatches
// ENTITY_RECORD  //  TYPE: DOCUMENT

Neuralink Blindsight

// OVERVIEW

One dispatch references Neuralink Blindsight in the context of Jeffrey Epstein's transhumanist funding network. According to the broadcast, the device represents Neuralink's second product and was scheduled to enter its first human trial in 2026, with the stated mechanism being direct stimulation of the visual cortex in blind patients. Nexor reports this detail within a broader examination of financiers and institutions connected to transhumanist research agendas.

// 1 APPEARANCES IN THE ARCHIVE

From Occult Bookshelf to Genetics Lab: Tracing Jeffrey Epstein's Transhumanist Funding Network
// FILE
2026-04-24

From Occult Bookshelf to Genetics Lab: Tracing Jeffrey Epstein's Transhumanist Funding Network

The DOJ's 3.5-million-page Epstein file release and 18,000 personal emails obtained by Bloomberg News reveal a documented funding network connecting Epstein to Harvard's Program for Evolutionary Dynamics, MIT's Media Lab, CRISPR gene-editing research, artificial general intelligence programs, and the Edge Foundation dinner circuit. The host argues this constitutes not eccentric philanthropy but a traceable architecture linking occult ideology and transhumanist philosophy to research programs now producing commercial technology at scale.

// RELATED ENTITIES